Targeting both wild-type EGFR and its drug-resistant mutants with erlotinib-aptamer conjugates
Yan Li, Jian H. Song, Ruixin Ge, Xiangrui Luo, Ping Zhou, Ping Zhou, Hanyue Lei, Fan Zhang, Wei Pan, Miao Chen, Jingrui Li, Xifeng Dong, Tianliang Li, Sijin Wu, Jun Zhou, Songbo Xie, Songbo Xie
Topics & Concepts
ErlotinibChemistryMutantAptamerConjugateDrugWild typePharmacologyEpidermal growth factor receptorBiochemistryMolecular biologyGeneReceptorMedicineMathematicsMathematical analysisBiologyLung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer therapeutics and mechanisms